Opko Health

OPK

Market cap $1.21B

BURLINGTON, N.C. and MIAMI , Sept.

OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.

Opko Health (OPK) Q2 Revenue Falls 14%

OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.

OPKO Health, Inc. (NASDAQ:OPK ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Adam E. Logal - Senior VP & CFO Elias Adam Zerhouni - President & Vice Chairman Phillip Frost - Chairman & CEO Yvonne Briggs - LHA Investor Relations Conference Call Participants Edward Andrew Tenthoff - Piper Sandler & Co., Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OPKO Health (OPK) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.01 per share a year ago.

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial ( NCT06655324 ).

COCONUT GROVE, Fla. , June 30, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today issued the following Interim CEO Update Shareholder Letter: To Our Shareholders: As interim CEO of NextPlat and on behalf of our Board of Directors and management team, I am writing to you to provide an update on our company and the actions being taken to drive the business forward.

MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative.